Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome

Clinical and Translational Gastroenterology

Volumn 7, Issue 5, 2016, Pages

  Acosta, Andres ^a   Camilleri, Michael ^a   Shin, Andrea ^a   Nord, Sara Linker ^a   Neill, Jessica O ^a   Gray, Amber V ^a   Lueke, Alan J ^a   Donato, Leslie J ^a   Burton, Duane D ^a   Szarka, Lawrence A ^a   Zinsmeister, Alan R ^a   Golden, Pamela L ^b   Fodor, Anthony ^c  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; BILE ACID; BUTYRIC ACID; CARBOXYLIC ACID; LACTULOSE; MANNITOL; PLACEBO; PROPIONIC ACID; RIFAXIMIN; SHORT CHAIN FATTY ACID;

ACCELERATION; ADULT; AGED; ARTICLE; ASCENDING COLON; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; EXCRETION; FECES ANALYSIS; FECES MICROFLORA; GASTROINTESTINAL TRACT SCINTISCANNING; HUMAN; INTENTION TO TREAT ANALYSIS; INTESTINE FLORA; INTESTINE MOTILITY; INTESTINE MUCOSA PERMEABILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; LONGITUDINAL STUDY; MICROBIAL COMMUNITY; MIDDLE AGED; NONHUMAN; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINAL BACTERIAL OVERGROWTH; SPECIES RICHNESS;

EID: 85122939744     PISSN: 2155384X     EISSN: None     Source Type: Journal    
DOI: 10.1038/ctg.2016.32     Document Type: Article

References (51)

1. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-Analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535 544.
2. Kassinen A, Krogius-Kurikka L, Mäkivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24 33.
3. Malinen E, Rinttilä T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-Time PCR. Am J Gastroenterol 2005; 100: 373 382.
4. Lyra A, Rinttilä T, Nikkilä J et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 2009; 15: 5936 5945.
5. Stephen AM, Haddad AC, Phillips SF. Passage of carbohydrate into the colon. Direct measurements in humans. Gastroenterology 1983; 85: 589 595.
6. Tana C, Umesaki Y, Imaoka A et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 512 519.
7. Kamath PS, Phillips SF, O'Connor MK et al. Colonic capacitance and transit in man: modulation by luminal contents and drugs. Gut 1990; 31: 443 449.
8. Spiller RC, Brown ML, Phillips SF. Decreased fluid tolerance, accelerated transit, and abnormal motility of the human colon induced by oleic acid. Gastroenterology 1986; 91: 100 107.
9. Nelson TA, Holmes S, Alekseyenko AV et al. PhyloChip microarray analysis reveals altered gastrointestinal microbial communities in a rat model of colonic hypersensitivity. Neurogastroenterol Motil 2011; 23: 169 177.
10. Winston J, Shenoy M, Medley D et al. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology 2007; 132: 615 627.
11. Le Gall G, Noor SO, Ridgway K et al. Metabolomics of faecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res 2011; 10: 4208 4218.
12. Malinen E, Krogius-Kurikka L, Lyra A et al. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol 2010; 16: 4532 4540.
13. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22 32.
14. Pimentel M, Park S, Mirocha J et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med 2006; 145: 557 563.
15. Sharara AI, Aoun E, Abdul-Baki H et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326 333.
16. Schoenfeld P, Pimentel M, Chang L et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: A pooled analysis of randomised, doubleblind, placebo-controlled trials. Aliment Pharmacol Ther 2014; 39: 1161 1168.
17. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: A retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006; 52: 89 95.
18. Scarpellini E, Giorgio V, Gabrielli M et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2013; 17: 1314 1320.
19. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011; 60: 334 340.
20. Lin EC, Massey BT. Scintigraphy demonstrates high rate of false-positive results from glucose breath tests for small bowel bacterial overgrowth. Clin Gastroenterol Hepatol 2015; 14: 203 208.
21. Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol 2014; 20: 2482 2491.
22. Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2016; 43: 37 49.
23. Talley NJ, Phillips SF, Wiltgen CM et al. Assessment of functional gastrointestinal disease: The Bowel Disease Questionnaire. Mayo Clin Proc 1990; 65: 1456 1479.
24. Camilleri M, McKinzie S, Busciglio I et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772 781.
25. Prytz H, Benoni C, Tagesson C. Does smoking tighten the gut? Scand J Gastroenterol 1989; 24: 1084 1088.
26. Suenaert P, Bulteel V, Den Hond E et al. The effects of smoking and indomethacin on small intestinal permeability. Aliment Pharmacol Ther 2000; 14: 819 822.
27. Sequeira IR, Lentle RG, Kruger MC et al. The effect of aspirin and smoking on urinary excretion profiles of lactulose and mannitol in young women: Toward a dynamic, aspirin augmented, test of gut mucosal permeability. Neurogastroenterol Motil 2012; 24: e401 e411.
28. Bjarnason I, Williams P, Smethurst P et al. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27: 1292 1297.
29. Deiteren A, Camilleri M, Bharucha AE et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 2010; 22: 415 423.e95.
30. Manabe N, Wong BS, Camilleri M et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010; 22: 293 e82.
31. Camilleri M, Nadeau A, Lamsam J et al. Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion. Neurogastroenterol Motil 2010; 22: e15 e26.
32. Lostia AM, Lionetto L, Principessa L et al. A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability. Clin Biochem 2008; 41: 887 892.
33. Hazen TC, Dubinsky EA, DeSantis TZ et al. Deep-sea oil plume enriches indigenous oil-degrading bacteria. Science 2010; 330: 204 208.
34. Probst AJ, Birarda G, Holman HY et al. Coupling genetic and chemical microbiome profiling reveals heterogeneity of archaeome and bacteriome in subsurface biofilms that are dominated by the same archaeal species. PLoS One 2014; 9: e99801.
35. Tagliacozzi D, Mozzi AF, Casetta B et al. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: A simple and rapid onestep method. Clin Chem Lab Med 2003; 41: 1633 1641.
36. Camilleri M, Acosta A, Busciglio I et al. Effect of colesevelam on fecal bile acids and bowel functions in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2015; 41: 438 448.
37. Wong BS, Camilleri M, Carlson P et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012; 10: 1009 1015.
38. Shin A, Camilleri M, Vijayvargiya P et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 1270 1275.
39. Guerrant GO, Moss CW, Lambert MA. Analysis of short-chain acids from anaerobic bacteria by high-performance liquid chromatography. J Clin Microbiol 1982; 16: 355 360.
40. Tangerman A, Nagengast FM. A gas chromatographic analysis of fecal short-chain fatty acids, using the direct injection method. Anal Biochem 1996; 236: 1 8.
41. Haas V, Böning C, Buhner S et al. Clinical relevance of measuring colonic permeability. Eur J Clin Invest 2009; 39: 139 144.
42. Dunlop SP, Hebden J, Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288 1294.
43. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012; 15: 474 479.
44. Pimentel M, Chang C, Chua KS et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci 2014; 59: 1278 1285.
45. Pistiki A, Galani I, Pyleris E et al. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents 2014; 43: 236 241.
46. Kim MS, Morales W, Hani AA et al. The effect of rifaximin on gut flora and Staphylococcus resistance. Dig Dis Sci 2013; 58: 1676 1682.
47. Pimentel M, Fodor AA, Golden P et al. Characterization of stool microbiota in subjects with IBS-D receiving repeat treatments with rifaximin in the TARGET 3 study. Gastroenterology 2015; 148: S655.
48. Ridlon JM, Alves JM, Hylemon PB et al. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 2013; 4: 382 387.
49. Camilleri M. Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. Aliment Pharmacol Ther 2015; 42: 818 828.
50. Rao AS, Camilleri M, Eckert DJ et al. Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol 2011; 301: G919 G928.
51. Camilleri M, Busciglio I, Acosta A et al. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol 2014; 109: 1621 1630